Steven D. Schwartz

A Phase II Randomized Double-Masked Trial of Pegaptanib, an Anti–Vascular Endothelial Growth Factor Aptamer, for Diabetic Macular Edema

Emmett T. Cunningham, Anthony P. Adamis, Michael M. Altaweel et al. · Ophthalmology · 2005 · 593 citations

Medicine, Ophthalmology, Pharmacotherapy +13

Enzymatic transition states and dynamic motion in barrier crossing

Steven D. Schwartz, Vern L. Schramm · Nature Chemical Biology · 2009 · 269 citations · Full text

Natural Sciences, Biochemistry, Biophysics +13

Maximum Tolerated Dose of a Humanized Anti–Vascular Endothelial Growth Factor Antibody Fragment for Treating Neovascular Age-Related Macular Degeneration

Philip J. Rosenfeld, Steven D. Schwartz, Mark S. Blumenkranz et al. · Ophthalmology · 2005 · 223 citations

Medicine, Ophthalmology, Pharmacotherapy +14

Progression of Geographic Atrophy in Age-related Macular Degeneration

Tiarnán D L Keenan, Elvira Agrón, Amitha Domalpally et al. · Ophthalmology · 2018 · 211 citations

Medicine, Ophthalmology, Vision Science +14

Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression

Emily Y. Chew, Traci E. Clemons, Elvira Agrón et al. · JAMA Ophthalmology · 2022 · 172 citations · Full text

Medicine, Oncology, Ophthalmology +16